Effectiveness and safety of lidocaine use (review)
Aleksandr V. Matveev1,2, Anatoliy Ye. Krasheninnikov3, Elena A. Egorova4, Elena A. Matveeva4
1National Scientific
Center of Pharmacovigilance, Moscow, Russia avmcsmu@gmail.com 2Medical Academy n.a. S.I. Georgievsky,
Crimean Federal University n.a. V.I. Vernadsky 3National Scientific Center of Pharmacovigilance, Moscow, Russia anatoly.krasheninnikov@drugsafety.ru 4Medical Academy n.a. S.I. Georgievsky - Crimean Federal University n.a. V.I. Vernadsky, Simferopol, Russia elena212007@rambler.ru
Keywords: ventricular arrhythmias, ventricular fibrillation, lidocaine, antiarrhythmic drugs
Abstract
Cardiac arrhythmias are
complications of many cardiovascular diseases. They quite often acquire
an unpredictable course and can result in the death. According to
epidemiology data, heart rhythm disorders lead to the sudden death of
about 200 thousand people in the Russian Federation annually. Sudden
cardiac death overtakes about 400 thousand outpatients and hospital
patients in the USA and about 280 thousand patients in Europe. The
unpredictability of the occurrence and the transience of cardiac
arrhythmias require urgent measures, including both non-pharmacological
(electrical pacing, electrical shock therapy) and pharmacotherapeutic
methods of treatment. This review is devoted to the study of the
clinical features of the lidocaine infusions in patients with
ventricular arrhythmias caused by an increase of the conducting
cardiomyocytes automatism. The article presents the results of
comparative effectiveness and safety studies of lidocaine prescribed for
the treatment of ventricular tachycardia and ventricular fibrillation
(in the absence of the effect of electro-impulse therapy). Lidocaine is
compared with other antiarrhythmic drugs such as amiodarone, sotalol,
bretylium tosylate and procainamide. Recommendations of ILCOR
(International Committee for Interaction in the Field of Resuscitation),
AHA (American Cardiology Association), ECS (European Cardiology
Society) and European Society for Resuscitation for the treatment of
refractory forms of ventricular arrhythmias and ventricular fibrillation
are also discussed.
|